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overall group (33% vs. 20%; p< 0.0001) and versus the atorvastatin group (34% vs. 
24%; p < 0.0001). ConClusions: Propensity score-matched analysis of high-risk 
patients initiating statins indicated that rosuvastatin was significantly more likely 
to reduce LDL-C compared with all other statins grouped together and compared 
with atorvastatin alone in this real world patient population.
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objeCtives: To compare the relative effectiveness and safety of all stroke preven-
tion agents in patients with atrial fibrillation (AF) through a systematic review and 
network meta-analyses. Methods: A search of MEDLINE, EMBASE, and CENTRAL 
was conducted (through December 2013) to identify Phase III randomized controlled 
trials of AF patients, comparing any two of the following agents: placebo, aspirin, 
aspirin and clopidogrel combination therapy (A+C), adjusted-dose warfarin (target 
INR 2.0-3.0), dabigatran (110 mg and 150 mg), rivaroxaban, apixaban, and edoxaban 
(high and low doses). We conducted fixed-effects Bayesian network meta-analyses 
to generate relative effectiveness estimates for the outcomes of interest (all stroke, 
ischemic stroke, myocardial infarction, overall mortality, major bleeding, intrac-
ranial hemorrhage, and fatal bleeding). For each outcome, agents were ranked 
according to their likelihood of being the best option. Results: We identified 12 
studies, comprising 81,771 patients. Compared to warfarin, dabigatran 150 mg (RR 
0.65, 95% CI 0.52-0.82) and apixaban (RR 0.80, 95% 0.66-0.96) reduced the risk of 
all strokes. Dabigatran 150 mg was also more effective than warfarin at reducing 
ischemic stroke risk (RR 0.77, 95% CI 0.59 – 0.99). All anticoagulants were more effec-
tive than A+C, aspirin and placebo at reducing the risk of ischemic and all strokes. 
All treatments were associated with a lower risk of major bleeding than warfarin, 
except for dabigatran 150 mg, rivaroxaban, A+C, and aspirin. Dabigatran 150 mg 
was most likely to be ranked best at reducing ischemic stroke risk, and low-dose 
edoxaban as best at reducing major bleeding risk. ConClusions: Anticoagulants 
effectively reduce the risk of ischemic and all strokes in AF patients, and are more 
effective than antiplatelets. Some novel anticoagulants are associated with lower 
stroke and/or major bleeding risk than warfarin. In addition to a drug’s safety and 
effectiveness, individual treatment should consider the patient’s underlying stroke 
and bleeding risk profile.
PCV18
ComPaRatiVe effiCaCy of new oRal antiCoagulantS foR StRoke 
PReVention in atRial fibRillation among PatientS with PRioR StRoke 
oR SyStemiC emboliSm
Cope S.1, Keen A.2, Chen M.2, Bergrath E.2
1Mapi, Toronto, ON, Canada, 2Mapi, Boston, MA, USA
objeCtives: Patients with atrial fibrillation (AF) and a previous stroke or tran-
sient ischaemic attack (TIA) have a high risk of stroke and may have a different 
baseline risk than patients without previous stroke or TIA, which may act as a 
treatment effect modifier. Therefore, the comparative efficacy of new oral antico-
agulants (NOACs) in terms of stroke or systemic embolism (SE) was assessed for 
the subgroup of patients with a previous stroke or TIA. Methods: A Bayesian net-
work meta-analysis (NMA) was performed for patients with previous stroke or TIA 
from three pivotal randomized controlled trials: ARISTOTLE, RE-LY, and ROCKET-AF, 
which compared apixaban, dabigatran, and rivaroxaban to warfarin, respectively. 
Parametric survival functions were used to model the hazard ratios (HR) over time 
for the compared interventions, and the difference in the shape and scale param-
eters of these functions was synthesized and indirectly compared. Results were 
compared to an analysis of constant HRs as well as to previous NMAs for this sub-
group. Results: The time-varying HRs for the treatments versus warfarin suggest 
that each NOAC is at least as efficacious as warfarin with respect to stroke and SE. 
The HR for dabigatran 150mg was fairly constant over time (range: 0.80-0.68). The 
HR for dabigatran 110mg decreased slightly over time (range: 1.82-0.40), whereas 
the HRs increased slightly over time for rivaroxaban (range: 0.61-1.34) and apixaban 
(range: 0.62-0.94). ConClusions: Based on the NMA of stroke or SE among patients 
with AF and a prior stroke or TIA, dabigatran 150mg and apixaban are expected to be 
comparable to warfarin; dabigatran 110mg is expected to be comparable to warfarin 
for the first 16 months and more efficacious up until 30 months; rivaroxaban is 
expected to more efficacious than warfarin for the first 4 months, and comparable 
to warfarin thereafter.
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objeCtives: In order to indirectly compare new oral anticoagulants (NOACs) for 
patients with atrial fibrillation (AF), several network meta-analyses (NMAs) have 
compared the number of patients with stroke or systemic embolism (SE) at study 
end. The aim of the present analysis was to assess the comparative efficacy of 
NOACs over the entire duration of the studies, including changes in compara-
tive efficacy over time, using the published cumulative hazard rates. Methods: 
A Bayesian NMA was performed using a fractional polynomial model synthesiz-
ing data from three pivotal randomized controlled trials: ARISTOTLE, RE-LY, and 
ROCKET-AF, which evaluated apixaban, dabigatran, and rivaroxaban, respectively, 
versus warfarin. Parametric survival functions were used to model the hazard rate 
over time for the compared interventions and the difference in the shape and 
scale parameters of these functions was synthesized and indirectly compared. 
The efficacy of NOACs was evaluated and compared to constant HRs from previ-
ous NMAs. Results: The time-varying hazard ratios (HRs) versus warfarin suggest 
that each NOAC is at least as efficacious as warfarin with respect to stroke and SE. 
The HR for dabigatran 110mg was fairly constant over time (range: 0.92-0.90). The 
HR for dabigatran 150mg decreased slightly over time (range: 0.78-0.56), whereas 
the HRs increased slightly over time for rivaroxaban (range: 0.59-1.17) and apixaban 
(range: 0.55-1.11). The HRs for each treatment comparison versus warfarin were 
transformed into cumulative hazard rates per treatment. ConClusions: Based on 
the NMA of stroke or SE among the intention to treat population with AF, dabigatran 
110mg is expected to be comparable to warfarin; dabigatran 150mg is expected to 
be comparable to warfarin for the first 5 months and more efficacious up until 30 
months; rivaroxaban and apixaban are expected to more efficacious than warfarin 
for the first 11 and 12 months, respectively, and comparable to warfarin thereafter.
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objeCtives: Despite the known benefit of low-density lipoprotein cholesterol 
(LDL-C) goal attainment of less than 70 mg/dL in a reduced risk of cardiovascular 
events, its effectiveness in acute coronary syndrome patients in Thailand is limited. 
This study aimed to assess the effect of LDL-C goal attainment on first composite 
cardiovascular outcomes. Methods: A retrospective cohort study was conducted 
using medical charts of patients who were hospitalized for acute coronary syndrome 
and were treated with statins at a tertiary care hospital in Thailand between 2009 
and 2012. After admission, patients were followed from the date of LDL-C goal 
assessment until the first event of composite cardiovascular outcomes (myocardial 
infarction, stroke, death). Median follow-up time was 544 days (interquartile range: 
224-887 days). Cox proportional hazard models were used to determine the effect 
of LDL-C goal attainment on the cardiovascular outcomes. Results: A total of 405 
patients were included. Mean age was 65 years (60% males). Twenty-seven percent 
of the patients attained a LDL-C goal of < 70 mg/dL, 38% had LDL-C between 70 
and 99 mg/dL and 35 % had LDL-C ≥ 100 mg/dL. Forty-six patients experienced a 
composite cardiovascular outcome. Patients achieving a LDL-C of < 70 mg/dL was 
associated with a lower composite cardiovascular outcome compared to patients 
with a LDL-C ≥ 100 mg/dL (adjusted HR= 0.41; 95% CI= 0.18 – 0.93; p-value= 0.034). 
Patients with a LDL-C between 70-99 mg/dL had a lower composite cardiovascular 
outcome compared to patients with a LDL-C ≥ 100 mg/dL but was not statistically 
significant (adjusted HR= 0.72; 95%CI= 0.37 – 1.42; p-value= 0.346). ConClusions: 
Acute coronary syndrome patients who received statins and achieved a LDL-C of 
< 70 mg/dL were more likely to have less cardiovascular outcomes, confirming the 
data from clinical trials that “the lower LDL-C the better”. Improvements in goal 
attainment for LDL-C are encouraging.
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objeCtives: Tachyarrhythmias is a significant burden to a variety of cardiovas-
cular conditions and increased rates of stroke, death. The aim of this study was 
to critically evaluate the current evidence on the use of cryocatheter ablation (CA) 
compared with radiofrequency catheter ablation (RFCA) in patients with tachyar-
rhythmias. Methods: We searched potentially relevant studies using electronic 
databases such as Ovid-Medline, Ovid-EMBASE, Cochrane library, and two local 
medical databases through April 2013. Two independent reviewers extracted data 
from each study using a standardized form. Disagreements between reviewers 
were resolved by discussion or in consultation with a third reviewer. The quality of 
the selected studies was assessed using the Cochrane risk of bias for randomized 
controlled trials (RCTs). A fixed-effects model was used to combine trials and the 
dichotomous data were presented as relative risk (RR) with 95% confidence intervals 
(CI). Results: A total of 9 RCTs representing 1,202 patients were included. Their 
methodological quality was mostly poor. In 3 trials of atrial flutter, cryoablation, 
in comparison with RFCA, did not result in statistically significant difference in 
freedom from atrial flutter (RR 0.97, 95% CI 0.90-1.05, P= 0.43, I2= 0%). The incidence 
of freedom from atrial fibrillation was 80% in the cryoablation group compared with 
63.3% in the RFA group; this difference was not significant (RR 1.26, 95% CI 0.91-1.75, 
P= 0.16). In paroxysmal supraventricular tachycardias (PSVT), cryoablation signifi-
cantly decreased freedom from AVNRT or clinical recurrence (RR 0.95, 95% CI 0.91-
0.98, P= 0.003, I2= 0%). Major complications were not reported in the trials and the 
incidence of complications did not reported significant different. ConClusions: 
There is limited evidence to confirm the relative advantages and disadvantages of 
cryoablation versus radiofrequency ablation in patients with tachyarrhythmias. 
Further rigorous RCTs with long-term follow up that overcome the many limitations 
of the current evidence are warranted.
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objeCtives: Atrial fibrillation (AF) is an irregular and often rapid heart rate that 
commonly causes poor blood flow to the body. Dabigatran and Warfarin have shown 
safety and efficacy for treatment of AF. The objective of this study was to conduct 
meta-analysis and present evidence for safety of Dabigatran versus Warfarin for 
treatment of AF. Methods: For this meta-analysis we included randomized con-
